Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18.

Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18.

Item
http://www.wikidata.org/entity/Q33552702
Integrative Development of a TLR8 Agonist for Ovarian Cancer ChemoimmunotherapyImmunotherapeutic approaches to ovarian cancer treatment.A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancerPrognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.Immunotherapy in ovarian cancer.Opportunities in immunotherapy of ovarian cancer.Cancer immunotherapy and nanomedicine.A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary periDoxorubicin-loaded phosphatidylethanolamine-conjugated nanoliposomes: in vitro characterization and their accumulation in liver, kidneys, and lungs in rats.Immunotherapy for ovarian cancer: what are the targets of the future?Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response
P2860

Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18.

Item
http://www.wikidata.org/entity/Q33552702
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Increased immunogenicity of su ...... posomal doxorubicin and IL-18.
@ast
Increased immunogenicity of su ...... posomal doxorubicin and IL-18.
@en
Increased immunogenicity of su ...... posomal doxorubicin and IL-18.
@nl
type
label
Increased immunogenicity of su ...... posomal doxorubicin and IL-18.
@ast
Increased immunogenicity of su ...... posomal doxorubicin and IL-18.
@en
Increased immunogenicity of su ...... posomal doxorubicin and IL-18.
@nl
prefLabel
Increased immunogenicity of su ...... posomal doxorubicin and IL-18.
@ast
Increased immunogenicity of su ...... posomal doxorubicin and IL-18.
@en
Increased immunogenicity of su ...... posomal doxorubicin and IL-18.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P932
P356
P1433
P1476
Increased immunogenicity of su ...... posomal doxorubicin and IL-18.
@en
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P932